(NASDAQ: CADL) Candel Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
Candel Therapeutics's earnings in 2026 is -$88,531,000.On average, 11 Wall Street analysts forecast CADL's earnings for 2026 to be -$114,249,869, with the lowest CADL earnings forecast at -$142,477,568, and the highest CADL earnings forecast at -$106,858,176. On average, 10 Wall Street analysts forecast CADL's earnings for 2027 to be -$88,065,216, with the lowest CADL earnings forecast at -$162,724,380, and the highest CADL earnings forecast at -$15,265,454.
In 2028, CADL is forecast to generate $6,909,626 in earnings, with the lowest earnings forecast at -$121,480,874 and the highest earnings forecast at $179,971,665.